Our Technology

DOTBODY TECHNOLOGY

DotBio's domain therapeutic antibody ("DotBody") technology platform is based on a human domain antibody germline which is highly stable and non-immunogenic.   

The DotBody technology has been extensively validated in clinical studies.

The use of in vitro libraries allows DotBio to generate “Dot”  modules against any target rapidly and at scale. Each Dot is optimized for modularity, target specificity, high potency, high expression, solubility, stability and low immunogenicity.  

DotBio’s key differentiation is the ability to produce hundreds of antibody prototypes in parallel, thereby speeding up the process of candidate molecule identification. This is made possible as DotBio generates different antibody prototypes by simply connecting the Dots.  

The DotBody technology is compatible with many antibody formats. These include:  

• Small antibodies without Fc region which are ideal for higher tissue penetration 

• Bi- and tri-specific antibodies generated by adding DotBody modules to monoclonal antibodies through protein fusion  

• Bi- and tri-specific antibodies generated by knob-into-hole technology 

• High valency molecules 

• Bi- and tri-specific ADCs through compatibility with ADC technologies